17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4′-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion

ACS Chemical Neuroscience

Volumn 7, Issue 3, 2016, Pages 297-304

  Zhang, Yan ^a   Williams, Dwight A ^a   Zaidi, Saheem A ^a   Yuan, Yunyun ^a   Braithwaite, Amanda ^b   Bilsky, Edward J ^b   Dewey, William L ^a   Akbarali, Hamid I ^a   Streicher, John M ^b   Selley, Dana E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

biased signaling; functional selectivity; Mu opioid receptor; nalbuphine; NAP; arrestin2

Indexed keywords

17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA (4' PYRIDYLCARBOXAMIDO)MORPHINAN; BETA ARRESTIN 2; CALCIUM ION; GAG PROTEIN; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALTREXAMINE DERIVATIVE; UNCLASSIFIED DRUG; MORPHINAN DERIVATIVE; NARCOTIC ANALGESIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CALCIUM CELL LEVEL; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SYNTHESIS; DYNAMICS; INTESTINE MOTILITY; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; SIMULATION; AGONISTS; ANIMAL; CELL LINE; CHEMISTRY; CHO CELL LINE; CONFOCAL MICROSCOPY; CRICETULUS; DRUG EFFECTS; GASTROINTESTINAL MOTILITY; HUMAN; MALE; METABOLISM; MOLECULAR MODEL;

ANALGESICS, OPIOID; ANIMALS; CELL LINE; CHO CELLS; CRICETULUS; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MICE; MICROSCOPY, CONFOCAL; MODELS, MOLECULAR; MORPHINANS; RECEPTORS, OPIOID, MU;

EID: 84962224127     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.5b00245     Document Type: Article

References (31)

1. Fredriksson, R., Lagerstrom, M. C., Lundin, L. G., and Schioth, H. B. (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints Mol. Pharmacol. 63, 1256-1272 10.1124/mol.63.6.1256
2. Overington, J. P., Al-Lazikani, B., and Hopkins, A. L. (2006) How many drug targets are there? Nat. Rev. Drug Discovery 5, 993-996 10.1038/nrd2199
3. Leff, P. (1995) The two-state model of receptor activation Trends Pharmacol. Sci. 16, 89-97 10.1016/S0165-6147(00)88989-0
4. Flordellis, C. S. (2012) The plasticity of the 7TMR signaling machinery and the search for pharmacological selectivity Curr. Pharm. Des. 18, 145-160 10.2174/138161212799040556
5. Kenakin, T. (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals Trends Pharmacol. Sci. 16, 232-238 10.1016/S0165-6147(00)89032-X
6. Rajagopal, S., Rajagopal, K., and Lefkowitz, R. J. (2010) Teaching old receptors new tricks: Biasing seven-transmembrane receptors Nat. Rev. Drug Discovery 9, 373-386 10.1038/nrd3024
7. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., Miller, K. J., Spedding, M., and Mailman, R. B. (2007) Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 320, 1-13 10.1124/jpet.106.104463
8. Venkatakrishnan, A. J., Deupi, X., Lebon, G., Tate, C. G., Schertler, G. F., and Babu, M. M. (2013) Molecular signatures of G-protein-coupled receptors Nature 494, 185-194 10.1038/nature11896
9. Raehal, K. M. and Bohn, L. M. (2014) beta-arrestins: Regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia Handb. Exp. Pharmacol. 219, 427-443 10.1007/978-3-642-41199-1-22
10. McNicol, E., Horowicz-Mehler, N., Fisk, R. A., Bennett, K., Gialeli-Goudas, M., Chew, P. W., Lau, J., and Carr, D. (2003) Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review J. Pain 4, 231-256 10.1016/S1526-5900(03)00556-X
11. DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X. T., Pitis, P. M., Gotchev, D., Yuan, C., Koblish, M., Lark, M. W., and Violin, J. D. (2013) A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine J. Pharmacol. Exp. Ther. 344, 708-717 10.1124/jpet.112.201616
12. McPherson, J., Rivero, G., Baptist, M., Llorente, J., Al-Sabah, S., Krasel, C., Dewey, W. L., Bailey, C. P., Rosethorne, E. M., Charlton, S. J., Henderson, G., and Kelly, E. (2010) μ-opioid receptors: Correlation of agonist efficacy for signalling with ability to activate internalization Mol. Pharmacol. 78, 756-66 10.1124/mol.110.066613
13. Li, G., Aschenbach, L. C., Chen, J., Cassidy, M. P., Stevens, D. L., Gabra, B. H., Selley, D. E., Dewey, W. L., Westkaemper, R. B., and Zhang, Y. (2009) Design, synthesis, and biological evaluation of 6alpha- A nd 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists J. Med. Chem. 52, 1416-1427 10.1021/jm801272c
14. Mitra, P., Venitz, J., Yuan, Y., Zhang, Y., and Gerk, P. M. (2011) Preclinical disposition (in vitro) of novel mu-opioid receptor selective antagonists Drug Metab. Dispos. 39, 1589-1596 10.1124/dmd.111.038588
15. Yuan, Y., Li, G., He, H., Stevens, D. L., Kozak, P., Scoggins, K. L., Mitra, P., Gerk, P. M., Selley, D. E., Dewey, W. L., and Zhang, Y. (2011) Characterization of 6alpha- A nd 6beta-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists ACS Chem. Neurosci. 2, 346-351 10.1021/cn2000348
16. Yuan, Y., Stevens, D. L., Braithwaite, A., Scoggins, K. L., Bilsky, E. J., Akbarali, H. I., Dewey, W. L., and Zhang, Y. (2012) 6beta-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists Bioorg. Med. Chem. Lett. 22, 4731-4734 10.1016/j.bmcl.2012.05.075
17. Sell, S. L., McMahon, L. R., and France, C. P. (2003) Relative efficacy of buprenorphine, nalbuphine and morphine in opioid-treated rhesus monkeys discriminating naltrexone J. Pharmacol. Exp. Ther. 306, 1167-1173 10.1124/jpet.103.051425
18. Zhang, R. and Xie, X. (2012) Tools for GPCR drug discovery Acta Pharmacol. Sin. 33, 372-384 10.1038/aps.2011.173
19. Yuan, Y., Zaidi, S. A., Stevens, D. L., Scoggins, K. L., Mosier, P. D., Kellogg, G. E., Dewey, W. L., Selley, D. E., and Zhang, Y. (2015) Design, Syntheses, and Pharmacological Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan Analogues as Opioid Receptor Ligands Bioorg. Med. Chem. 23, 1701-15 10.1016/j.bmc.2015.02.055
20. Kostenis, E., Waelbroeck, M., and Milligan, G. (2005) Techniques: Promiscuous Galpha proteins in basic research and drug discovery Trends Pharmacol. Sci. 26, 595-602 10.1016/j.tips.2005.09.007
21. Kowal, D., Zhang, J., Nawoschik, S., Ochalski, R., Vlattas, A., Shan, Q., Schechter, L., and Dunlop, J. (2002) The C-terminus of Gi family G-proteins as a determinant of 5-HT(1A) receptor coupling Biochem. Biophys. Res. Commun. 294, 655-659 10.1016/S0006-291X(02)00535-1
22. Burford, N. T., Wehrman, T., Bassoni, D., O'Connell, J., Banks, M., Zhang, L., and Alt, A. (2014) Identification of selective agonists and positive allosteric modulators for micro- A nd delta-opioid receptors from a single high-throughput screen J. Biomol. Screening 19, 1255-1265 10.1177/1087057114542975
23. Zhang, Y., Braithwaite, A., Yuan, Y., Streicher, J. M., and Bilsky, E. J. (2014) Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6alpha-(isoquinoline-3′-ca rboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand Eur. J. Pharmacol. 736, 124-130 10.1016/j.ejphar.2014.04.041
24. Kang, M., Maguma, H. T., Smith, T. H., Ross, G. R., Dewey, W. L., and Akbarali, H. I. (2012) The role of beta-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract J. Pharmacol. Exp. Ther. 340, 567-576 10.1124/jpet.111.186320
25. Yu, Y., Cui, Y., Wang, X., Lai, L. H., Wang, C. L., Fan, Y. Z., Liu, J., and Wang, R. (2007) In vitro characterization of the effects of endomorphin 1 and 2, endogenous ligands for mu-opioid receptors, on mouse colonic motility Biochem. Pharmacol. 73, 1384-1393 10.1016/j.bcp.2007.01.011
26. Fickel, J., Bagnol, D., Watson, S. J., and Akil, H. (1997) Opioid receptor expression in the rat gastrointestinal tract: A quantitative study with comparison to the brain Mol. Brain Res. 46, 1-8 10.1016/S0169-328X(96)00266-5
27. Pan, Y. X. (2005) Diversity and complexity of the mu opioid receptor gene: Alternative pre-mRNA splicing and promoters DNA Cell Biol. 24, 736-750 10.1089/dna.2005.24.736
28. Wisler, J. W., Xiao, K., Thomsen, A. R., and Lefkowitz, R. J. (2014) Recent developments in biased agonism Curr. Opin. Cell Biol. 27, 18-24 10.1016/j.ceb.2013.10.008
29. Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K., and Granier, S. (2012) Crystal structure of the micro-opioid receptor bound to a morphinan antagonist Nature 485, 321-326 10.1038/nature10954
30. Zaidi, S. A., Arnatt, C. K., He, H., Selley, D. E., Mosier, P. D., Kellogg, G. E., and Zhang, Y. (2013) Binding mode characterization of 6alpha- A nd 6beta-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: Application of the 'message-address' concept in development of mu opioid receptor selective antagonists Bioorg. Med. Chem. 21, 6405-6413 10.1016/j.bmc.2013.08.042
31. Tehan, B. G., Bortolato, A., Blaney, F. E., Weir, M. P., and Mason, J. S. (2014) Unifying family A GPCR theories of activation Pharmacol. Ther. 143, 51-60 10.1016/j.pharmthera.2014.02.004